Ribavirin (ICN-1229)

Catalog No.S2504 Synonyms: NSC-163039, RTCA, Tribavirin

For research use only.

Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin), a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.

Ribavirin (ICN-1229) Chemical Structure

CAS No. 36791-04-5

Selleck's Ribavirin (ICN-1229) has been cited by 19 publications

Purity & Quality Control

Choose Selective Antiviral Inhibitors

Biological Activity

Description Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin), a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.
In vitro

Ribavirin significantly reduces the efficiency with which progeny subgenomic replicons transfect new cells in the replicon system, although ribavirin has little effect on levels of HCV replication. Ribavirin increases the mutation frequency of HCV, with the highest rates of mutations being found in the NS5A-encoding region. Ribavirin enhances TH1 while inhibiting T 2 cytokine production by stimulated T cells. [1] Ribavirin shows antiviral activity against a variety of RNA viruses and is used in combination with interferon-alpha to treat hepatitis C virus infection. Ribavirin reduces infectious poliovirus production to as little as 0. 00001% in cell culture. [2] Ribavirin's antiviral activity is exerted directly through lethal mutagenesis of the viral genetic material. [3] Ribavirin markedly reduces viral-induced parameters of macrophage activation at physiologic concentrations (up to 500 mg/mL). Ribavirin inhibits the production of IL-4 by Th2 cells, whereas it does not diminish the production of IFN-gamma in Th1 cells. [4] Ribavirin exhibits antiviral activity against a broad range of both DNA and RNA viruses in vitro. Ribavirin is a cytostatic agent and causes a reduction in synthesis of DNA, RNA and proteins in exposed cells. Ribavirin is thought to induce a switch in T-helper cell phenotype from type 2 to type 1. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
E6SM cell lines MnnPSpVv[3Srb36gZZN{[Xl? M2DaNWVn\mWldHn2[UBkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgTIVzeGW|IIPpcZBt\XhidnnyeZMuOSiKU2[tNUkhNyC2aIntbY5mKGurbnHz[UBl\W[rY3nlcpQhMFSNLTnCNlAxPiBxIG\NW|E5OzdiaX7keYNm\CCleYTvdIF1cGmlaYT5JIJ6KDVyJTDpckBGPlOPIHPlcIwhdGmwZYOsJGVEPTB;MD6wNFUh|ryP MorQNVE1QTV3OE[=
MDCK cells NV2ydmF5TnWwY4Tpc44h[XO|YYm= NUTx[XJpOyCmYYnz Mm\rRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTY5ndHWnborhJGIhfmm{dYOgLGIwUEtxNT:3NkkhcW6oZXP0[YQhcW5iTVTDT{Bk\WyuczDhd5Nme3OnZDDhd{B3cXK3cz3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHHmeIVzKDNiZHH5d{BjgSCvaXPyc5Nkd3CrYzDhcoFtgXOrczygSWM2OD1yLkC5OEDPxE1? NFLNeIkzOzFzN{G3Ny=>
mouse L1210 cells M1TscmZ2dmO2aX;uJIF{e2G7 M165cVIxNTZyIH3pcpM> NH;HenhKdmirYnn0bY9vKG:oIFnNVGRJKGmwIH3veZNmKExzMkGwJINmdGy|IHHzd4V{e2WmIHHzJIZwem2jdHnvckBw\iCdMjy4MVNJZWi7cH;4ZY51cGmwZTDmdo9uKFt{LEitN2heUU2SIHHmeIVzKDJyIITvJFYxKG2rboOsJGlEPTB;MTFOwG0> NIS2VIEzOjV3NUG1Ni=>
human CEM cells Mo\TSpVv[3Srb36gZZN{[Xl? NXv5XZBQOjBvNkCgcYlvew>? NX3JZVhJUW6qaXLpeIlwdiCxZjDJUXBFUCCrbjDoeY1idiCFRV2gZ4VtdHNiYYPz[ZN{\WRiYYOg[o9zdWG2aX;uJI9nKFt{LEitN2hecHmyb4jhcpRpcW6nIH\yc40hYzJuOD2zTH1KVVBiYX\0[ZIhOjBidH:gOlAhdWmwczygTWM2OD1zIN88US=> NF;RWWUzOjV3NUG1Ni=>
BHK21 cell line Mn3CSpVv[3Srb36gZZN{[Xl? M2nreGlvcGmkaYTpc44hd2ZiV3XzeEBPcWynII\pdpV{KF[OUDDy[ZBtcWOxbjDpckBDUEt{MTDj[YxtKGyrbnWsJGVEPTB;MT6xJO69VQ>? M1\DdlE3PTN7NECy
HeLa cell MlXhSpVv[3Srb36gZZN{[Xl? M1LBbGVn\mWldHn2[UBkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgdoV{eGm{YYTvdpkhe3mwYYD0bYFtMFKVVjmgeolzfXNvaX7keYNm\CCleYTvdIF1cGmlaYT5JIJ6KDVyJTDpckBJ\UyjIHPlcIwhdGmwZYOsJGVEPTB;MT61JO69VQ>? M{PU[VEyPDl3NUi2
MDCK cells MWLGeY5kfGmxbjDhd5NigQ>? M17OZ|M3KGh? NUPlfWRjSW62aXnu[ox2\W68YTDhZ5Rqfmm2eTDh[4FqdnO2IHnu[ox2\W68YTDBJJZqenW|IFixUlEhcW6oZXP0[YQhcW5iTVTDT{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[W[2ZYKgN|YhcHK|LDDJR|UxRTFwOTFOwG0> MVqyNlM1OTl2Mx?=
MDBK cells Mk\RSpVv[3Srb36gZZN{[Xl? MVqyJIRigXN? M{HCTmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGJwfmmwZTD2bZJidCCmaXHydohm[SC4aYL1d{AyNU6DRFygRXRESyCYUkWzOEBqdm[nY4Tl[EBqdiCPRFLLJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iC4aYLhcEBkgXSxcHH0bIlkKGWoZnXjeEBi\nSncjCyJIRigXNiYoSgUXRUKGG|c3H5MEBGSzVyPUSuOkDPxE1? NHj0cIczOjl2NEOzNy=>
african green monkey Vero cells NFvOcmdHfW6ldHnvckBie3OjeR?= MYq1JIRigXN? MWHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDSV3YhSTJiaX7m[YN1\WRiaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhXmW{bzDj[YxteyCjZoTldkA2KGSjeYOgZpkheGyjcYXlJJJm\HWldHnvckBie3OjeTygSWM2OD15IN88US=> MoTYNlA{PTl6OUi=
HEL cells MYjGeY5kfGmxbjDhd5NigQ>? MmjLNk0{KGSjeYO= NGHFfFNCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJ\XKyZYOgd4lueGyneDD2bZJ2eyBzIFvPV{Bqdm[nY4Tl[EBqdiCKRVygZ4VtdHNiYYPz[ZN{\WRiYYOgdJJwfGWldHnvckBnem:vII\pdpV{NWmwZIXj[YQh[3m2b4DheIhw\2WwaXPpeJkh[W[2ZYKgNkB1dyB|IHThfZMh[nliTWTUJIF{e2G7LDDFR|UxRTFyIN88US=> MnywNlAxOzR5MUG=
HEK293 cells MXnGeY5kfGmxbjDhd5NigQ>? MUmyOEBp MXnJcohq[mm2aX;uJI9nKGmwZnz1[Y57[SCDII\pdpV{KFKQQT3k[ZBmdmSnboSgVm5CKHCxbInt[ZJie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAzPCCqcoOgZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NVUh|ryP NV;HdoxrOjR|MUO3N|A>
human BE(2)-C cells M{LM[mZ2dmO2aX;uJIF{e2G7 NGTSO2MyQC1{MDDo NFjiVG9CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBY\XO2ZYLuJIVyfWmwZTDlcoNmeGijbH;tfYVtcXSrczD2bZJ2eyCrbn\lZ5Rm\CCrbjDoeY1idiCERTiyLU1EKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxiUl7BJJJmeGyrY3H0bY9vKGGodHXyJFE5KHSxIEKwJIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUC9NVYh|ryP NXvu[5FpOjRzNUG5OVQ>
human HuH7-J20 cells MmPDSpVv[3Srb36gZZN{[Xl? NH;SfVZCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJS1ZiSl\INUBqdm[nY4Tl[EBqdiCqdX3hckBJfUh5LVqyNEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKGyrZnWgZ5lkdGViYomgcYVie3W{aX7nJJNm[3KndHXkJIFtc2GuaX7lJJBpd3OyaHH0ZZNmKGyndnXsJJBz\WmwY4XiZZRm\CC5aYToJINmdGy|IH\vdkAyKGi{IH\vcIxwf2WmIHL5JJZqemGuIHnuc4N2dGG2aX;uJIZweiB|IHjyd{Bu\WG|dYLl[EBifCB5MjDodpMtKEWFNUC9N|AvPCEQvF2= NH3oSZMzPjR{OEi3NC=>
human MT4 cells Mn;3R5l1d3SxeHnjxsBie3OjeR?= NHr6ZY06PiCq Mn3TR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXQ1KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGNEPTB;M{Gg{txO M4rCN|E6PDh{NEix
human HuH7 cells MmTsR5l1d3SxeHnjxsBie3OjeR?= MlLXN{Bl[Xm| MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIlv\mWldHXkJJdqfGhiSFPWNYIh[W[2ZYKgN{Bl[Xm|IHL5JG1VWyCjc4PhfUwhS0N3ME2zNkDPxE1? NHm5Z4UzOjFyMEK1Oi=>
human KB cells M2H1NmZ2dmO2aX;uJIF{e2G7 MY[3NkBp NVK1e2FRSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhWmirbn;2bZJ2eyC2eYDlJFE{KGmwZnXjeIVlKGmwIHj1cYFvKEuEIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDh[pRmeiB5MjDodpMhemWuYYTpeoUhfG9iY3;ueJJwdA>? NGLLfWg4OjJ5M{C=
human KB cells MXXGeY5kfGmxbjDhd5NigQ>? M{LjSVEuOTByMDFOwIcwdWx? NHXxXJg4OiCq Moj5RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgVohqdm:4aYL1d{B1gXCnIEGzJIlv\mWldHXkJIlvKGi3bXHuJGtDKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCjdDCxJJRwKDFyMECgeYcwdWxiYX\0[ZIhPzJiaILz MWmyNVEzOzR?
Assay
Methods Test Index PMID
Western blot p53 / p-p53 / p21 / Mdm2 ; EZH2 / p-ERK / ERK / p-eIF4E / eIF4E / p21 ; Cyclin D1 ; p-AKT / AKT / pBP1 / BP1 22962590 29487714 21415224
Growth inhibition assay Cell number 21415224

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 244.20864
Formula

C8H12N4O5

CAS No. 36791-04-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04283513 Not yet recruiting Drug: Virazole Hemorrhagic Fever U.S. Army Medical Research and Development Command June 2021 Phase 2
NCT04335123 Completed Drug: Losartan COVID-19 University of Kansas Medical Center April 4 2020 Phase 1
NCT04285034 Completed -- Lassa Fever University of Oxford November 26 2019 --
NCT03889106 Unknown status Drug: Ribavirin Lassa Fever University of Oxford|National Institute for Health Research United Kingdom|Kenema Government Hospital|London School of Hygiene and Tropical Medicine|Public Health England March 1 2019 --
NCT03585725 Terminated Drug: Ribavirin Follicular Lymphoma|Mantle Cell Lymphoma Weill Medical College of Cornell University|Memorial Sloan Kettering Cancer Center September 26 2018 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Ribavirin (ICN-1229) | Ribavirin (ICN-1229) ic50 | Ribavirin (ICN-1229) price | Ribavirin (ICN-1229) cost | Ribavirin (ICN-1229) solubility dmso | Ribavirin (ICN-1229) purchase | Ribavirin (ICN-1229) manufacturer | Ribavirin (ICN-1229) research buy | Ribavirin (ICN-1229) order | Ribavirin (ICN-1229) mouse | Ribavirin (ICN-1229) chemical structure | Ribavirin (ICN-1229) mw | Ribavirin (ICN-1229) molecular weight | Ribavirin (ICN-1229) datasheet | Ribavirin (ICN-1229) supplier | Ribavirin (ICN-1229) in vitro | Ribavirin (ICN-1229) cell line | Ribavirin (ICN-1229) concentration | Ribavirin (ICN-1229) nmr